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Background: Although omic-based discovery approaches can provide powerful tools for biomarker identification,
several reservations have been raised regarding the clinical applicability of gene expression studies, such as their
prohibitive cost. However, the limited availability of antibodies is a key barrier to the development of a lower cost
alternative, namely a discrete collection of immunohistochemistry (IHC)-based biomarkers. The aim of this study was
to use a systematic approach to generate and screen affinity-purified, mono-specific antibodies targeting
progression-related biomarkers, with a view towards developing a clinically applicable IHC-based prognostic
biomarker panel for breast cancer.
Methods: We examined both in-house and publicly available breast cancer DNA microarray datasets relating to invasion
and metastasis, thus identifying a cohort of candidate progression-associated biomarkers. Of these, 18 antibodies were
released for extended analysis. Validated antibodies were screened against a tissue microarray (TMA) constructed from a
cohort of consecutive breast cancer cases (n = 512) to test the immunohistochemical surrogate signature.
Results: Antibody screening revealed 3 candidate prognostic markers: the cell cycle regulator, Anillin (ANLN); the
mitogen-activated protein kinase, PDZ-Binding Kinase (PBK); and the estrogen response gene, PDZ-Domain Containing 1
(PDZK1). Increased expression of ANLN and PBK was associated with poor prognosis, whilst increased expression of
PDZK1 was associated with good prognosis. A 3-marker signature comprised of high PBK, high ANLN and low PDZK1
expression was associated with decreased recurrence-free survival (p < 0.001) and breast cancer-specific survival (BCSS)
(p < 0.001). This novel signature was associated with high tumour grade (p < 0.001), positive nodal status (p = 0.029),
ER-negativity (p = 0.006), Her2-positivity (p = 0.036) and high Ki67 status (p < 0.001). However, multivariate Cox regression
demonstrated that the signature was not a significant predictor of BCSS (HR = 6.38; 95% CI = 0.79-51.26, p = 0.082).
Conclusions: We have developed a comprehensive biomarker pathway that extends from discovery through to
validation on a TMA platform. This proof-of-concept study has resulted in the identification of a novel 3-protein
prognostic panel. Additional biochemical markers, interrogated using this high-throughput platform, may further
augment the prognostic accuracy of this panel to a point that may allow implementation into routine clinical practice.
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Breast cancer is a heterogeneous disease driven by a
continuum of mutations and abnormal gene/protein ex-
pression that controls the tumourigenic phenotype and
molecular mechanisms underpinning the complexity of
its clinical behaviour [1]. To select systemic therapies,
current treatment guidelines combine traditional prog-
nostic factors (stage, tumour size, histologic grade, nodal
status) with estrogen receptor (ER), progesterone recep-
tor (PR) and human epidermal growth factor receptor 2
(Her2) expression status. However, these conventional
prognostic algorithms are insufficient to capture the
biologic diversity of breast cancer and impede effective
tailoring of individualised treatment strategies [2]. In the
post-genomic era, advances in prognostic and predictive
models are beginning to capture this heterogeneity, not
least with the recent generation of a new molecular classi-
fication consisting of at least ten different breast cancer
subtypes [3-6]. Molecular profiling of cancer tissues has
aided the development of targeted therapies, improved
our understanding of treatment resistance, and helps
better predict patient prognosis. This knowledge has
allowed personalised breast cancer therapeutic regimens
to become an achievable goal.
The cornerstone of molecular profiling has historically
been transcriptomics which has transformed our under-
standing of the complexity of the underlying signalling
pathways and interactions within a breast tumour, as well
as allowing the identification of gene expression signa-
tures associated with patient outcome [4,7]. Conse-
quently, clinical development of transcriptomic profiling
tools has dramatically escalated, augmenting standard
diagnostic and prognostic information obtained from trad-
itional clinicopathological variables [8]. The most clinically
advanced prognostic gene expression signatures in breast
cancer are MammaPrint [7,9] and OncotypeDx [10],
which are currently the subject of large-scale prospective
randomised control trials to assess their utility for stratifi-
cation of breast cancer patients [11-13].
Whilst transcriptomic approaches have undoubtedly
enabled the acceleration of translational pathology, pro-
viding an excellent platform for omic-based discovery
[13,14], reservations have been raised regarding the clin-
ical applicability of gene expression studies given their
prohibitive cost, often reliance on frozen tissue, quality
assurance issues and the advanced technical expertise
required to utilise the technology [2]. Crucially, mRNA
transcription does not necessarily translate to protein
expression, and it is not uncommon to observe a dis-
crepancy between mRNA and protein expression [15,16].
As proteins are one of the primary effectors of the cell,
protein-based assays may be more clinically relevant as
biomarkers in personalised medicine. Effective implemen-
tation of personalised cancer therapy depends upon thesuccessful identification and translation of informative
biomarkers to aid treatment provision. In a prior review,
we described the contribution of antibody-based proteo-
mics for fast-tracking the development of new diagnostic
assays that are crucial to achieving personalisation of
cancer therapy [17]. The systematic generation and
validation of specific antibodies offers a high-throughput
mechanism for the functional exploration of the proteome
and a logical approach for fast-tracking the translation
of identified biomarkers [17]. Whilst DNA microarray
technology provides an excellent platform for biomarker
discovery, it would now appear that IHC and genomic
sequencing may play an increasingly important role in
the clinical management of breast cancer [2]. Tissue
microarrays (TMAs) are an ideal platform for rapid de-
velopment of an IHC profile, allowing multiple targets
to be systematically assessed, and reduce an assay to
clinical utility [3-5,8,18-23].
In this proof-of-concept study, we used a novel high-
throughput system, using affinity-purified, mono-specific
antibodies, to translate protein targets from gene expres-
sion studies into clinically applicable IHC-based prog-
nostic panels for breast cancer.
Methods
Selection of candidate biomarkers from transcriptomic
datasets
Thirty-one genes were selected from an in-house ana-
lysis of the van ’t Veer study [7], using a Between Group
Analysis (BGA) method identifying the top 100 good
and poor prognosis genes [24,25]. From this list, we
considered the top 15 genes associated with good prog-
nosis and the top 16 genes associated with poor progno-
sis. Another 25 genes of interest were selected from a
transcriptomic study of ductal carcinoma in situ (DCIS)
to invasive ductal carcinoma (IDC) progression, with a
particular focus on transcripts that were up-regulated in
the invasive component [26] (Additional file 1: Table S1).
Patients
The TMAs used in this study were derived from a refer-
ence cohort of 512 consecutive invasive breast cancer
cases diagnosed at the Department of Pathology, Malmö
University Hospital, Malmö, Sweden between 1988 and
1992 and have been previously described [27-29]. The
median patient age was 65 years (range 27–96) and me-
dian follow-up time regarding disease-specific and over-
all survival was 11 years (range 0–17). Duplicate cores
for each patient were reported as consensus scores. Each
patient was assigned a unique identifier that was then
linked to an anonymised ethics board-approved database
containing follow-up information. Patients with recur-
rent disease and previous systemic therapies were ex-
cluded. Two hundred and sixty-three patients were
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which were classified as breast cancer-specific deaths. Eth-
ical permission was obtained from the Local Ethics Com-
mittee at Lund University (Dnr 613/02), whereby
informed consent was deemed not to be required, but
opting out was an option.TMA construction
The TMAs were constructed using a manual tissue arrayer
(MTA-1, Beecher Inc., WI, USA). PBK and PDZK1 were
screened on a TMA inclusive of all 512 cases from the ref-
erence cohort with 0.6 mm duplicate tissue cores extracted
from each donor block. ANLN was screened on a second
generation TMA inclusive of 498 cases from the reference
cohort, with 1.0 mm duplicate tissue cores extracted from
each donor block and transferred to the recipient block.
The total number of cores per block was limited to ~ 200
(100 patients), with a total of 5 blocks arrayed.Antibody generation
The Human Protein Atlas (HPA) [30] use a high-throughput
method to generate affinity-purified, mono-specific anti-
bodies raised to all non-redundant human proteins [31].
Protein epitope sequence tag (PrEST)-specific antibodies
represent unique regions of each protein target. Rabbit
polyclonal antisera immunised with His6ABP-PrEST anti-
gens derived from a subset of the 56 targets of interest
described above (Additional file 1: Table S1) were purified
by a two-step immunoaffinity protocol to obtain pure
mono-specific antibodies [32].Cell culture
A panel of breast epithelial cell lines were selected to test
antibody specificity, including MCF-7, BT474, T47D,
SKBR3, MDA-MB-231 and Hs578T cells. The Hs578T
(i8) invasive subclone was a kind gift from Dr. Susan
McDonnell (School of Chemical & Bioprocess Engineering,
University College Dublin, Ireland) and was derived from
the parental Hs578T cell line (also denoted as Hs578T(P))
by sequential selection through the BD MatrigelW
Invasion Chamber assay system [33]. All remaining cell
lines were purchased from the European Collection of
Cell Cultures (Wiltshire, UK). The MCF-7, BT474,
T47D, SKBR3, and MDA-MB-231 cell lines were cul-
tured in DMEM supplemented with 10% (w/v) foetal
calf serum, 2 mM L-glutamine, 50 IU/ml penicillin, and
50 μg/ml streptomycin sulphate. The Hs578T variants
were also supplemented with 10 μg/ml bovine insulin.
Cells were maintained in humidified air with 5% CO2 at
37°C. Studies of protein expression were performed on
cells at 70-80% confluence. All cell lines were routinely
screened for Mycoplasma contamination.Western blot analysis
Total protein was extracted from sub-confluent cells
by the addition of radioimmunoprecipitation assay buf-
fer (RIPA), followed by centrifugation at 16,000 g for
20 min at 4°C. The supernatants were removed and
the protein levels determined using the bicinchoninic
acid (BCA) method (Pierce, IL). Samples containing
50 μg aliquots of protein were separated by sodium
dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-
PAGE), on a 12% polyacrylamide gel under reducing
conditions. Following electrophoresis, proteins were trans-
ferred to polyvinylidene fluoride membrane. Membranes
were blocked in 5% non-fat milk for 1 hr at room
temperature. Protein expression was detected using rabbit
mono-specific polyclonal anti-human antibodies (HPA,
Sweden) applied overnight at 4°C (PDZK1 1:1000 dilution;
PBK, ANLN 1:500). Membranes were washed in TBS-T
(Tris buffered saline with 0.1% Tween 20) and incubated
for 1 hr with horseradish peroxidase (HRP)-conjugated
anti-rabbit immunoglobulin (all antibodies: 1:5000 dilution).
The blots were again washed in TBS-T. HRP was detected
using Enhanced Chemiluminescence plus (Amersham
Biosciences, UK). Chemiluminescence was detected by
autoradiography using X-ray film. Membranes were
stripped and re-probed with anti-β-actin (1:5000 dilution;
Abcam, UK) as a loading control.
Cell pellet arrays
In order to validate the Western blotting results in the
IHC setting, a cell pellet array was constructed and IHC
was performed on the same panel of breast cancer cell
lines. Cells were trypsinised and fixed for 1 hr in 10%
formalin, centrifuged at 500 x g for 10 minutes, washed
twice with PBS and re-suspended in 0.8% agarose. The
tumour cell-containing agarose plugs were processed
through gradient concentrations of alcohols before being
cleared in xylene and washed in molten paraffin. These
cell pellets were embedded in paraffin and arrayed in
quadruplicate 1.0 mm cores using a manual tissue
arrayer (MTA-1, Beecher Inc, WI). IHC was carried out
on 5 μm sections.
Immunohistochemical analysis
Sections of cell pellet arrays or TMAs were deparaffinised
in xylene and rehydrated in descending gradient alcohols.
Heat-mediated antigen retrieval was performed using
10 mM sodium citrate buffer (pH 6.0) in a PT module
(LabVision, UK) for 15 min at 95°C. The LabVision IHC
kit (LabVision, UK) was used for staining. Endogenous
peroxidase activity was blocked by incubation with 3%
hydrogen peroxide for 10 min. Sections were blocked
for 10 min in UV blocking agent. Rabbit polyclonal
anti-human antibodies (HPA, Sweden) were applied at
individual optimised dilutions for 1 hr (PDZK1 1:50
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phosphate buffered saline with 0.1% Tween 20 (PBS-T).
Subsequently, primary antibody enhancer was applied for
20 min, and sections were washed again in PBS-T. Sec-
tions were then incubated with HRP polymer for 15 min,
washed in PBS-T and then developed for 10 min using
diaminobenzidine (DAB) solution (LabVision, UK). After
antigen retrieval, all incubations and washing stages
were carried out at room temperature. The sections
were counterstained in haematoxylin, dehydrated in al-
cohol and xylene and mounted using an automated
coverslipper (Leica, Germany). As a negative control,
the primary antibodies were substituted with PBS-T.
Evaluation of immunohistochemical staining
Slides were scanned at 20X magnification using a ScanScope
XT slide scanner (Aperio Technologies, CA). Cores with
less than 30% tissue present or less than 100 cells were
discarded to avoid manual selection bias. Tumour samples
were evaluated by at least two independent observers
including one pathologist, and the maximum values of
the two cores was used. All discordant cases were
re-evaluated and a consensus reached between both
observers. ANLN expression, as a nuclear marker, was
categorised based on percentage nuclear staining such
that 0 = ≤1%, 1 = 2-25%, 2 = 26-75% and 3= > 75%. PDZK1
expression, as a cytoplasmic marker, was scored on a semi-
quantitative scale depending on intensity of cytoplasmic
staining: ranging from 0–3, where 0 is negative, 1 is weakly
positive, 2 is medium positive and 3 is strongly positive.
The intensity distribution (ID) scoring method was used
with the cytoplasmic marker, PBK, which incorporated in-
tensity of the scoring with percentage of cells stained [34].
Annotation of gene expression data and hybridisation
probes
Gene expression data sets were downloaded from the
Gene Expression Omnibus [35] or authors’ websites in
the form of raw data files where possible (Additional
file 1: Table S2) [36-43]. Relevant gene expression and
clinical data was extracted from ten publicly available
datasets incorporating approximately 1,300 samples. Where
raw data was not available, the normalised data as pub-
lished by the original study was used. In the case of the
Affymetrix datasets (.cel files), gene expression values
were called using the robust multichip average method
and data were quantile normalised using the Bioconductor
package, affy [44,45]. For the dual-channel platforms, data
were loess normalised using the Bioconductor package
limma [46]. Hybridisation probes were mapped to Entrez
gene IDs to gene-centre the data [47]. The Entrez gene
IDs corresponding to the array probes targeting genes of
interest were obtained from the Gene database at NCBI
[48] (ANLN:54443, PBK:55872, PDZK1:5174). If therewere multiple probes for the same gene, the probes were
averaged for that gene. All calculations were carried out in
the R statistical environment [49].
Statistical analysis of transcriptomic meta-analysis data
Gene expression data from ten publicly available datasets
were included in a meta-analysis to evaluate the individ-
ual prognostic significance of candidate proteins at the
transcriptomic level, as previously described (Additional
file 1: Table S2) [36-43]. Once a sample was assigned to
a particular group, the 10 datasets were combined and a
global survival analysis was performed. Each dataset was
considered separately when determining which group a
sample belonged to, due to the variability across differ-
ent platforms. Recurrence-free survival (RFS) was con-
sidered the survival end point. Median mRNA levels
established the cut-off for high and low expression for
each biomarker. Survival curves of the dichotomised
groups were compared using the log-rank test for signifi-
cance. The survival curve was based on Kaplan-Meier
estimates. Cox regression analysis was used to calculate
hazard ratios (HR) and to adjust for all available clinical
parameters. Across the meta-analysis, the available clin-
icopathological parameters were lymph node status,
tumour grade and ER status.
Statistical analysis of consecutive cohort data
The χ2 test and Fisher’s exact test were used to evaluate
associations between protein expression and clinico-
pathological variables in the cohort. Pearson’s correlation
coefficient was used to evaluate correlation between
expression of the three independent markers. Kaplan-
Meier analysis and the log-rank test were used to illustrate
differences between recurrence-free survival (RFS) or breast
cancer-specific survival (BCSS), according to differential
protein expression. Cox proportional hazards regression
was used to estimate proportional hazards for the individual
protein expression and other clinicopathological variables
in both univariate and multivariate models. The clinico-
pathological variables available for the consecutive cohort
included tumour size, age at diagnosis, histological type,
grade, nodal, ER, PR, Ki67 and Her2 status. All calculations
were carried out using IBM SPSS Statistics version 20.0.
Results
High-throughput screening platform for mono-specific
antibodies against candidate breast cancer progression-
related biomarkers
In this study, fifty-six gene targets of interest were se-
lected for generation of polyclonal affinity-purified anti-
PrEST anti-sera on the basis of links with breast cancer
progression at the mRNA level in previously published
transcriptomic datasets [7,25,26]. Of the 56 gene targets
submitted to the HPA, 18 mono-specific antibodies were
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bodies was initially validated by Western blot analysis on
a panel of discrete breast cancer cell lines with varying
invasive properties. Ten out of the 18 antibodies
exhibited specificity via Western blot analysis, with the
expected molecular weight being observed (ANLN,
PDZK1 and PBK shown in Figure 1A). Specificity was
further verified by performing IHC on the correspondingFigure 1 Expression of PBK, PDZK1 and ANLN protein in breast cance
across a panel of 7 breast cancer cell lines of varying invasive capabilities. A
knockdown (data not shown). B: Validation of the PBK and PDZK1 antibodi
(x20 magnification). The T47D, MDA-MB-231 and Hs578T (i8) cell lines are s
staining. C: Representative cores of ANLN, PDZK1 and PBK protein expressio
intensity. Vertical red line represents the cut-off between low and high proformalin-fixed, paraffin-embedded (FFPE) breast cancer
cell lines (subset shown in Figure 1B). Seven antibodies
showed concordant results for Western blot analysis and
IHC staining in the breast cancer cell line cohort. Fi-
nally, three antibodies (PDZK1, ANLN, PBK) were suc-
cessfully optimised on full-face paraffin embedded
sections of breast cancer tissues and subsequently se-
lected for screening on TMAs (Figure 1C).r. A: Western blot analysis of PBK, PDZK1 and ANLN protein expression
NLN antibody specificity also validated by shRNA-mediated
es by immunohistochemistry in a panel of FFPE breast cancer cell lines
pecifically shown. Antibody positivity is indicated by the brown DAB
n from the TMAs graded on a scale from 0 to 3+ for protein staining
tein expression for each biomarker.
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tumours determined by IHC
As shown in Figure 1A, antibodies against anillin (ANLN),
PDZ-Domain Containing 1 (PDZK1) and PDZ-Binding
Kinase (PBK) demonstrated specificity via Western blot
analysis and exhibited concordant IHC staining on cell
pellet arrays across 7 breast cancer cell lines. Antibody
specificity was further validated using Western blotting
and antigen microarrays (Additional file 2: Figure S1).
Four hundred and seventy-nine of the original cohort
of 512 tumours (93.6%) were available for analysis of
ANLN immunostaining, with 280/512 (54.7%) available
for analysis of PDZK1 immunostaining and 292/512
(57.0%) available for analysis PBK immunostaining, with
several sets of tumours not available for analysis due to
core loss. Two hundred and fifty-two out of 512 (49.2%)
tumours had a score for each of the three biomarkers,
while 260 were not available for analysis due to core loss
in the case of at least one of the 3 markers under evalu-
ation. The clinicopathological variables for the available
(n = 252) and unavailable (n = 260) tumours were com-
pared using χ2 analysis and Fisher’s Exact test, with
no significant difference being seen in terms of patient
age (p = 0.927), tumour size (p = 0.582), tumour grade
(p = 0.271), histological type (p = 0.368), nodal status
(p = 0.479), ER status (p = 0.578), PR (p = 0.612), Her2
(p = 0.192) or Ki67 (p = 0.754) expression between avail-
able and unavailable samples.
Using semi-quantitative analysis, IHC staining was scored
on a scale of 0–3 based on intensity of staining (ANLN
and PDZK1) or based on ID scoring (PBK) (see Figure 1C).
High ANLN protein expression were classified as tumours
with a staining intensity >1, and low expression classified
as tumours with a staining intensity ≤1. High PDZK1 pro-
tein expression was classified as tumours with a staining
intensity >2, and low expression classified as tumours with
a staining intensity ≤2. PBK staining was classified using
the ID scoring method (percentage of cells stained multi-
plied by intensity score), where the threshold for high
PBK protein staining was >48. On the basis of this
analysis, 309 evaluable tumours (64.5%) were classified
as expressing high levels of ANLN and 170 (35.5%) ex-
pressing low levels of ANLN; 43 tumours (15.4%) were
classified as expressing high levels of PDZK1 versus 237
(84.6%) expressing low levels of PDZK1, and 105 (36.0%)
expressing high levels of PBK with 187 (64.0%) expressing
low levels of PBK.
Correlation of ANLN, PDZK1 and PBK protein expression
with clinicopathological parameters
On the basis of the IHC thresholds for ANLN, PDZK1 and
PBK expression detailed above, we investigated the associa-
tions between individual protein expression and a variety of
well-defined clinicopathological variables in the TMAcohort (Additional file 1: Table S3). ANLN expression cor-
related positively with tumour size (p = 0.006), high tumour
grade (p < 0.001), Her2 status (p < 0.001), Ki67 status
(p < 0.001) and invasive ductal carcinomas (IDC) (p < 0.001),
while correlating negatively with age at diagnosis (p = 0.019),
ER status (p < 0.001) and PR status (p = 0.049). PBK ex-
pression correlated positively with high grade tumours
(p < 0.001) and Ki67 status (p < 0.001). PDZK1 expression
correlated positively with low grade tumours (p = 0.010).
There was a significant correlation between ANLN and
PBK expression (Pearson’s R = 0.206, p < 0.001, n = 283),
yet there was no correlation between ANLN and
PDZK1 (p = 0.410), and PBK and PDZK1 (p = 0.543).
Single marker analysis of ANLN, PDZK1 and PBK protein
expression associated with patient survival
The relationship between differential expression of ANLN,
PDZK1 and PBK and outcome was subsequently exam-
ined. Kaplan-Meier analysis demonstrated that increased
PDZK1 protein expression was associated with an im-
proved BCSS (p = 0.047), with high levels of ANLN and
PBK protein expression being associated with reduced
BCSS (ANLN: p < 0.001; PBK: p = 0.011) (Figure 2A).
Univariate Cox regression analysis showed that high
ANLN protein expression (HR = 3.91; 95% CI = 1.85-
8.29; p < 0.001) and high PBK protein expression
(HR = 2.33; 95% CI = 1.19-4.55; p = 0.013) were associated
with reduced BCSS, while differential PDZK1 protein ex-
pression (HR = 0.17; 95% CI = 0.02-1.24; p = 0.080) was
not associated with prolonged BCSS. Both ANLN and
PBK were significant independent predictors of BCSS
when adjusted for other well-established variables, using
multivariate Cox regression analysis (see Additional file 1:
Table S4).
The relationship between ANLN, PBK and PDZK1
protein and RFS was examined. Kaplan-Meier analysis
showed that high levels of ANLN and PBK protein
expression being associated with reduced RFS (ANLN:
p < 0.001; PBK: p = 0.021) (Figure 2B). PDZK1 protein
expression was not associated with RFS (p = 0.239). To
compare the prognostic impact of ANLN with established
factors, Cox regression analysis was performed. Univariate
Cox regression analysis confirmed high ANLN expression
(HR = 2.41; 95% CI = 1.61-3.62; p < 0.001) and high PBK
expression were associated with reduced RFS (HR = 1.64;
95% CI = 1.07-3.62; p = 0.023). High PDZK1 expression
was not associated with prolonged RFS (HR = 0.65;
95% CI = 0.31-1.35; p = 0.243). In the multivariate Cox
proportional hazards model, ANLN was a significant
independent predictor of reduced RFS (HR = 2.14; 95%
CI = 1.00-4.58; p = 0.038). However, multivariate Cox
regression analysis demonstrated that that PBK and
PDZK1 protein expression were not independent pre-
dictors of RFS (Additional file 1: Table S5).
Figure 2 Prognostic role of ANLN, PBK and PDZK1 at the protein and mRNA level in breast cancer. A: Kaplan-Meier curves demonstrating
high expression of PBK and ANLN protein and low expression of PDZK1 protein associated with reduced BCSS. B: Kaplan-Meier curves
demonstrating high expression of PBK and ANLN protein and low expression of PDZK1 protein associated with reduced RFS. C: Meta-analysis of
publicly available transcriptomic data demonstrating high expression of the ANLN and PBK mRNA and low expression of PDZK1 mRNA associated
with reduced RFS. P-value represents log-rank test.
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In order to validate these results in a larger number at
patients, we performed a meta-analysis of ANLN, PDZK1
and PBK expression from independent transcriptomic
datasets, previously described in detail (Additional file 1:
Table S2) [36-43]. Using median mRNA expression levels
as a cut-off, this meta-analysis displayed high concordance
with protein expression data, whereby high expression
of ANLN mRNA (p < 0.0001), high expression of PBKmRNA (p = 0.0002) and low expression of PDZK1 mRNA
(p = 0.0006) were associated with decreased RFS (Figure 2C).
This further confirms the role of ANLN and PBK as
poor prognostic markers and PDZK1 as a good prog-
nostic marker.
By combining these markers into a prognostic signa-
ture, we could test the strength of the panel depending
on the relative expression of each marker. Patients
with the poor prognostic signature (i.e. high expres-
sion of ANLN mRNA, high expression of PBK mRNA
and low expression of PDZK1 mRNA) had reduced
Figure 3 Transcriptomic screen identifies three markers as a
prognostic panel in breast cancer. Our three-marker model is
associated with RFS at mRNA level using a meta-analysis of 10
independent transcriptomic datasets.
Table 1 Association of panel score with
clinicopathological parameters in the consecutive cohort
Panel score
0 1 2 3 p-value
Variables (n = 9) (n = 77) (n = 105) (n = 61)
Mean Age 0.765
≤50 1 (11.1) 11 (14.3) 15 (14.3) 12 (19.7)
>50 8 (88.9) 66 (85.7) 90 (85.7) 49 (80.3)
Tumour Size 0.475
≤2cm 6 (66.7) 54 (70.1) 66 (62.9) 35 (57.4)
>2cm 3 (33.3) 23 (29.9) 39 (37.1) 26 (42.6)
Histological type 0.378*
Indeterminate 0 (0.0) 8 (10.4) 5 (4.8) 7 (11.5)
Ductal 6 (66.7) 47 (61.0) 75 (71.4) 46 (75.4)
Lobular 2 (22.2) 14 (18.2) 12 (11.4) 4 (6.6)
Tubular 1 (11.1) 5 (6.5) 7 (6.7) 1 (1.6)
Medullary 0 (0.0) 0 (0.0) 4 (3.8) 2 (3.3)
Mucinous 0 (0.0) 3 (3.9) 2 (1.9) 1 (1.6)
Tumour Grade <0.001*
I 4 (44.4) 25 (32.9) 23 (21.9) 4 (6.6)
II 5 (55.6) 42 (55.3) 38 (36.2) 19 (31.1)
III 0 (0.0) 9 (11.8) 44 (41.9) 38 (62.3)
Nodal status 0.029
N0 4 (66.6) 45 (68.2) 49 (51.0) 41 (73.2)
N1+ 2 (33.3) 21 (31.8) 47 (49.0) 15 (26.8)
Unknown 3 11 9 5
ER status 0.006
ER Negative 0 (0.0) 4 (5.3) 21 (20.6) 14 (23.7)
ER Positive 8 (100) 72 (94.7) 81 (79.4) 45 (76.3)
Unknown 1 1 3 2
PR status 0.061
PR Negative 2 (28.6) 16 (26.2) 32 (37.2) 25 (51.0)
PR Positive 5 (71.4) 45 (73.8) 54 (62.8) 24 (49.0)
Unknown 2 16 19 12
Her2 status 0.036
0 - 2 + 6 (85.7) 69 (97.2) 88 (87.1) 48 (81.4)
3+ 1 (14.3) 2 (2.8) 13 (12.9) 11 (18.6)
Unknown 2 6 4 2
Ki67 status <0.001
0 - 10% 5 (62.5) 48 (62.3) 33 (32.7) 7 (11.7)
11 - 100% 3 (37.5) 29 (37.7) 68 (67.3) 53 (88.3)
Unknown 1 0 4 1
*Linear-by-linear χ2 analysis; Others by Fisher’s Exact test.
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http://www.biomedcentral.com/1471-2407/13/175RFS (p < 0.0001, n = 1,308) (Figure 3). Using Multivari-
ate cox regression analysis and adjusting for known
clinical parameters, these observations remained inde-
pendent of lymph node status, tumour grade and ER
status (HR= 1.49, 95% CI = 1.08-2.05, p= 0.018, n = 699).
Correlation of 3-protein prognostic panel with
clinicopathological parameters and patient survival
Based on the above results, we combined ANLN, PDZK1
and PBK into a 3-protein prognostic model. A scoring
technique was devised attributing a score of +1 to each
poor prognostic marker exhibited on immunostaining of
individual tumour cores (i.e., high ANLN, high PBK and
low PDZK1) (Figure 1C). The summed scores for each
patient ranged from 0–3 (good → poor prognosis) and,
to establish a prognostic model, was dichotomised into
a good prognostic set, ‘Signature A’ (incorporating
scores 0 and 1), and a poor prognostic set, ‘Signature B’
(incorporating scores 2 and 3).
Two hundred and fifty-two patients of the original co-
hort had a score for all 3 candidate biomarkers. Associa-
tions of the established panel scores (0–3) to known
clinicopathological parameters were assessed (Table 1).
The panel score was found to correlate with high tumour
grade (p < 0.001), positive nodal status (p = 0.029), ER-
negativity (p = 0.006), Her2-positivity (p = 0.036) and high
Ki67 status (p < 0.001) status (Table 1).
When separated into 0, 1, 2 and 3 scores, a higher panel
score was significantly associated with poorer BCSS and
RFS (Figure 4A and 4C). The dichotomised 3 biomarker
panel was significantly predictive of BCSS (p < 0.001)
(Figure 4B) and RFS (p < 0.001) (Figure 4D). To compare
the prognostic impact of the panel score with establishedfactors, Cox regression analysis was performed. Univariate
Cox regression analysis demonstrated that high panel
scores (2 and 3) were significantly associated with reduced
BCSS (HR = 16.36; 95% CI = 2.23-120.30; p = 0.006) and
Figure 4 Novel 3-protein panel as a prognostic model in breast cancer. Kaplan-Meier curves demonstrating that the three-protein panel is
associated with reduced RFS and BCSS; A: Individual scores and BCSS, B: Dichotimised panel and BCSS, C: Individual scores and RFS, D: Dichotimised
panel and RFS.
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http://www.biomedcentral.com/1471-2407/13/175reduced RFS (HR = 3.33; 95% CI = 1.75-6.31; p < 0.001)
(summarised in Table 2; all variables listed in Additional
file 1: Table S6 and Additional file 1: Table S7). However,
multivariate Cox regression demonstrated that the dichot-
imised 3-panel score was not a significant predictor of
either BCSS (HR = 6.38; 95% CI = 0.79-51.26, p = 0.082)
or RFS (HR = 1.46; 95% CI = 0.66-3.19, p = 0.348), when
adjusted for other well-established variables, namely
tumour grade, tumour size, age at diagnosis, ER, PR,
Her2, Ki67 and nodal status. It must be noted whenTable 2 Cox univariate and multivariate analysis of RFS and B
BCSS
HR (95% CI)
All patients (n = 252)
3 marker panel Univariate
Signature A 1.00
Signature B 16.36 (2.23 - 120.30)
3 marker panel Multivariate*
Signature A 1.00
Signature B 6.38 (0.79 – 51.26)
* Multivariate analysis included adjustment for tumour size (continuous), tumour grall variables except for PR status are adjusted for, the
3-panel score becomes an independent predictor of BCSS
(HR = 11.66; 95% CI = 0.1.50-90.68, p = 0.019).
Discussion
Gene expression profiling has successfully yielded new in-
sights into the biologic diversity of breast cancer identify-
ing several distinct molecular subtypes (such as luminal A,
luminal B, basal and Her2) differing markedly in prognosis
and in the repertoire of therapeutic targets they expressCSS in the consecutive cohort
RFS
p HR (95% CI) p
Univariate
1.00
0.006 3.33 (1.75 – 6.31) <0.001
Multivariate*
1.00
0.082 1.46 (0.66 – 3.19) 0.348
ade, age at diagnosis (continuous), nodal, ER, PR, Her2 and Ki67 status.
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http://www.biomedcentral.com/1471-2407/13/175[4,5,50]. Importantly, these intrinsic subtypes play a key
role in prediction of disease recurrence, treatment re-
sponse, and the provision of new insights into onco-
genic pathways and metastatic progression [51]. It is
striking that, in the face of what is considered a hetero-
geneous tumour, molecular signatures of tumour sub-
types consistently emerge across independent cohorts
with diverse genetic and environmental backgrounds
[52-54]. This reproducibility is a crucial primary de-
scriptor of disease phenotype in the early detection of
disease, lending key prognostic and predictive information.
Antibody-based proteomics occupies a pivotal space
within the cancer biomarker discovery and validation
pipeline, facilitating the high-throughput evaluation of
candidate markers [17]. In this context, IHC-based high-
throughput technology has been demonstrated as an
effective platform for identification of protein surro-
gates of these intrinsic breast cancer subtypes by various
groups [23,53]. For example, a panel of 5 proteins detected
by immunohistochemistry was shown to be prognostic for
ER-positive breast cancer [8]. The use of validated IHC
surrogates should provide more clinically applicable assays
in the future, due to ease of accessibility, low technical
demand, cost-effectiveness and applicability to FFPE
tissue. Despite these advances, the development of IHC-
based assays has been globally impaired by the limited
availability of high quality antibodies and lack of rigorous
validation of emerging biomarkers. However, the devel-
opment of comprehensive antibody resources and
streamlining of reporting standards, promises to help over-
come these obstacles [31,55].
In this study, we sought to determine whether insights
from gene expression studies relating to breast cancer
progression could be translated into a robust prognostic
protein model using a discrete set of IHC markers. This
proof-of-concept strategy generated a prognostic panel
using high-throughput biomarker screening in combin-
ation with a devised panel scoring technique. We con-
firmed that a high panel score was significantly associated
with reduced RFS (p < 0.0001; n = 1,038), using a meta-
analysis of publicly available breast cancer transcriptomic
datasets. The panel was an independent prognostic marker
using multivariate Cox regression analysis (p = 0.018,
HR = 1.49, 95% CI = 1.080-2.054, n = 699). This strategy
revealed a novel 3-marker prognostic model signifi-
cantly predictive of RFS based on ANLN, PDZK1 and
PBK expression patterns.
Next, we validated this signature on a protein-based
platform using TMA technology. The 3-protein panel score
correlated with known pathological prognostic variables,
including tumour grade and lymph node status, ER, Her2
and Ki67 status. Univariate Cox regression analysis of RFS
demonstrated that high panel scores, indicative of poor
prognosis, were significantly associated with reduced RFS.However, multivariate analysis demonstrated that the
3-marker panel score was not a significant predictor of
either BCSS (HR = 6.38; 95% CI = 0.79-51.26, p = 0.082)
or RFS (HR = 1.46; 95% CI = 0.66-3.19, p = 0.348), when
adjusted for other well-established variables. We noted
that the 3-panel score becomes an independent predictor
of BCSS (HR = 11.66; 95% CI = 0.1.50-90.68, p = 0.019),
when all variables except for PR status are adjusted for.
This may be due to marginal associations of our individ-
ual markers with these variables (e.g. PDZK1 and ER
status: p = 0.041; PDZK1 and PR status: p = 0.074). Since
both PDZK1 and PR are surrogate markers for ER activ-
ity, we note that the strength of this panel may be
skewed by the presence of PDZK1 protein in the panel.
Thus, we hypothesise that additional or alternate biochem-
ical markers, interrogated using this high-throughput plat-
form, may further augment the prognostic accuracy of this
algorithm to a point that may allow implementation into
routine clinical practice.
Interestingly, the 3 proteins that comprise this panel
model are associated with distinct pathways in cancer
biology. ANLN, initially characterised as a human homo-
logue of anillin, a Drosophila actin-binding protein, is es-
sential for the organisation of actin cables in the cleavage
furrow, and plays a key role in cytokinesis and cell cycle
progression [56-59]. ANLN has been demonstrated as a
marker of poor prognosis, relating to aggressive cancer
phenotypes [60]. In breast cancer, a transcriptomic study
of DCIS to IDC breast cancer progression identified
ANLN up-regulation in invasive tumour specimens rela-
tive to the pre-invasive phenotype [26]. Our study con-
firms the role of ANLN as a marker of poor prognosis, at
the protein level, in an independent breast cancer cohort.
PBK phosphorylates p38MAPK during mitosis, is consid-
ered a marker for cellular proliferation and is also impli-
cated in DNA damaging sensing and repair [61,62]. PBK is
associated with poorer prognosis in lung cancer [63], is
up-regulated in IDC relative to DCIS at the transcriptomic
level [26], and may be a promising molecular target for
treatment of breast cancer [64]. Our findings further
support the role of PBK as a marker of poor prognosis
in breast cancer, with expression of PBK also associated
with the histological markers of proliferation, Ki67 and
tumour grade. PDZK1 is a known estrogen response gene
in breast cancer, with proposed roles in signal transduc-
tion, cell polarity and ion exchange gating [65,66]. An
in-house statistical re-analysis of the genes assessed
by van’t Veer and colleagues in the development the
70-gene prognostic signature identified PDZK1 as a
marker of good prognosis in breast cancer [24], which
we confirmed at the protein level in this study. The
present study successfully validates these gene expression
findings at the mRNA level, and also translates them at
the protein level.
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http://www.biomedcentral.com/1471-2407/13/175However, further studies are warranted at the in vitro
and in vivo level, to help further interrogate the func-
tional background of each of these markers in breast
cancer progression. It will be necessary to further valid-
ate these findings with additional independent cohorts
of samples to meet accepted international validation
guidelines [55]. Although the literature is conflicting
with regard to the best way to incorporate histopath-
ology, IHC phenotypes, and gene expression data into
an accurate classification system, our findings further
support the key role of IHC prognostic models for current
breast cancer management.
Conclusions
We have developed a comprehensive biomarker develop-
ment pathway, extending from discovery through to valid-
ation on TMAs, that can yield novel multi-protein panel
signatures for use as a prognostic determinant in breast
cancer. Such developments represent an important trans-
lational gateway into the era of individualised medicine for
patients with newly diagnosed breast cancer.
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